Inventory of Supplemental Information
Supplemental Tables S1 & S2 detail the MIC values for the lipopeptides for Gram-negative and -positive bacteria strains.
Supplemental Tables S3 details the binding affinity of the lipopeptides for isolated bacterial lipopolysaccharide (LPS) determined by a dansyl-polymyxin displacement assay. Supplemental Tables S3 details plasma protein binding of lipopetides determined by equilibrium dialysis using pooled human plasma. The supplemental experimental procedures provide a detailed description of the synthesis of the lipopeptides. Supplemental figure S1 shows the static time-kill kinetics of lipopeptide FADDI-019 and colistin against a colistin-resistant P.aeruginosa isolate. Supplemental figure S2 shows the haemolytic effect of lipopeptides after 1 hour exposure to human red blood cells. >128  >128  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32  >32   FADDI-KP003  >32  128  >32  >32  >32  >32  >32  32  >32  >32  >32  >32  32  32  >32  >32  >32   FADDI-KP012  16  32  8  16  32  32  32  16  8  >32  16  16  16  16  32 >32 >32 Crude cyclic peptides were purified by reversed phase HPLC on a Agilent 1200 quaternary pump system, photodiode array detector (214 nm), employing a PhenomenexAxia column (Luna C8(2), 50 x 21.3 mm ID) eluting with a gradient of 60% acetonitrile in 0.1% aqueous TFA, over 60 minutes at a flow rate of 5 mL/min.
Synthesis of Fmoc-L-Cys(S-Hexyl)-OH
Fmoc-Cys(S-Hexyl)-OH was prepared from Fmoc-L-Cys-OH by reaction with Bromohexane (2eq) in a (1:1) mixture of dimethylformamide, 10% sodium carbonate solution overnight. The reaction solution was diluted with water and acidified with concentrated hydrochloric acid whilst cooling in an ice/water bath. Acetonitrile was then added to the reaction mixture, which was lyophilised overnight. The solid material obtained was extracted into diethylether which was then concentrated under nitrogen.The crude Fmoc-L-Cys(S-Hexyl)-OH was isolated by lyophilization from a mixture of acetonitrile and water and used without further purification. The purity was >90% as estimated by reversed-phase HPLC. FADDI-039 was synthesised as described above to give the FADDI-039 TFA salt as a white solid in a yield of 6.1 mg. The purity was >95% as estimated by reversed-phase HPLC. The compound was confirmed as having the correct molecular weight by ESI- 
Synthesis of FADDI-063 (TFA salt)
Synthesis of the protected linear peptide (coupling of residues 1-10 and N-terminal octanoyl) was carried out using out on a CEM Liberty Microwave automated peptide synthesizer using standard Fmoc solid phase peptide chemistry. Specifically, synthesis was undertaken using TCP-Resin, pre-loaded with Fmoc-Thr(tBu)-OH (loading 0.78 mmol/g), 0.1 mmol scale (128 mg of resin).
Coupling of the Fmoc-amino acids was performed using the default instrument protocol: 5 molar equivalents (relative to resin loading) of Fmoc amino acid and HCTU in DMF with activation in situ, using 10 molar equivalents of DIPEA. This was carried out for 2 min at room temperature then for 4 min at 50°C (25W microwave power). Fmoc deprotection was performed using the default instrument protocol: 20% piperidine in dimethylformamide (1, x 30 s, 1 x 3 min) at 75°C (35 W microwave power). The Acm protecting group of the D-cysteine residue at position 6 was removed by treating the resin with 5 eq of iodine in DMF for 30 min, followed by 10 eq of dithiothreitol and 20 eq of DIPEA in DMF for 30 min. The resin was then treated with 3eq of benzylbromide and 6 eq of DIPEA in DMF for 2 h. The resin was washed with DMF (4 × 2 min) then treated with 3% hydrazine in DMF (4 × 15 min) to remove the ivDde group. The resin was washed with DMF (4 x 2 min), MeOH (2 x 2 min) and diethylether (1 x 2min) and air dried under vacuum suction. The protected linear peptide was then cleaved from the resin by washing the resin with 1% TFA in DCM (1 x 5 min, 3 x 10 min). The resulting residue was dissolved in 50% acetonitrile / water and freeze dried overnight. The crude protected linear peptide obtained was used in the next step without further work up. The protected linear peptide was dissolved in DMF (10 mL) to which DPPA , 0.3 mmol, 0.65 µL (3 molar equivalents relative to the loading of the resin) and DIPEA 0.6 mmol, 104 µL (6 molar equivalents relative to the loading of the resin) were added. This solution was stirred at room temperature overnight. The reaction solution was then concentrated under vacuum overnight. The resulting residue was taken up in a solution of 5% TIPS in TFA and stirred at room temperature for 1.5 h. The TFA was removed under a stream of nitrogen and the crude cyclic peptide precipitated with cold diethyl ether. The resulting precipitate was collected by centrifugation and air-dried in a fume food to give the crude cyclic peptide as a residue. The resulting residue was taken up in milli-Q water and de-salted using a Vari-Pure IPE SAX column. The resulting solution containing the crude cyclic peptide was subjected to RP-HPLC purification. Fractions collected were analysed by LC-MS as described above. The combined fractions were freeze-dried for two days to give the FADDI-063 TFA salt as a white solid in a yield of 12.3 mg. The purity was >95% as estimated by reversed-phase HPLC at 214 nm. 
